Prostate Cancer Research
News: Treatment and Outcomes
- 4/17/2014 Quarter of Prostate Cancer Patients May Abandon 'Watchful Waiting' Approach | European study tracked how many men came back for regular checkups over 13 years
- 4/1/2014 Cialis May Not Prevent Impotence in Men Treated for Prostate Cancer | Study sees little value in taking the drug during radiation treatment
- 3/6/2014 NEJM Study Finds Surgery May Benefit Younger Prostate Cancer Patients | Study adds fodder to the operate vs. 'watch and wait' debate
- 3/4/2014 Statins and Prostate Cancer | As the science comes together, risk of aggressive disease may be abated with use, but little effect on indolent, early prostate cancers
- 2/24/2014 New Drug Options in Advanced Prostate Cancer Raise Questions on Treatment order | Medscape Video Presentation
- 12/20/2013 Moving the Dial to Cure; Can Targeted Radiotherapy actually eradicate tumors in men with advanced prostate cancer? | Until recently radiation therapy for advanced prostate cancer was only used to alleviate pain; now it has been shown to extend life
- 11/26/2013 Number of Circulating Tumor Cells May Predict Survival in Men with Metastatic Treatment-Resistant Prostate Cancer; May Aid Delivery of Personalized Cancer Care | Enumeration of Circulating Tumor Cells for Clinical Decision Making
- 11/21/2013 The Prostate Cancer Foundation Unveils Major Initiative to Improve Accuracy of Laboratory Cancer Studies | Best Practices in Cell Line Authentication
- 11/15/2013 Researchers Identify Cell Type That May Be Early Inducer of Prostate Cancer | With efforts from the Prostate Cancer Foundation and the U.S. prostate cancer advocacy community, led by the Prostate Cancer Roundtable, the 2012 budget for Congressionally Directed Medical Research Programs was preserved
- 11/12/2013 21st Century Medicine—Synthetically Engineered Cancer Biomarkers (video) | At this year’s Prostate Cancer Foundation’s 20th annual scientific retreat, attendees were dazzled by research out of MIT that uses nanoparticles for early cancer detection and monitoring as well as sussing out tiny blood clots in the body
- 11/04/2013 Teaching an Old Drug New Tricks to Fight Prostate Cancer | Their novel drug candidates kill tumor cells by activating an enzyme that turns off key cancer-promoting proteins
- 9/25/2013 New Urine Test for Prostate Cancer Available; Unlike PSA Test, is Ultra-Specific for Prostate Cancer | A new urine test for prostate cancer is now available
- 9/25/2013 Building a Better Mousetrap to catch Prostate Cancer | New urine test for prostate cancer improves utility of the PSA blood test, increases doctors’ ability to pick out high-risk tumors from low-risk tumors in patients, and may help tens of thousands of men avoid unnecessary biopsies
- 8/23/2013 Letters from Bozeman – Kenneth May, Jr., MD, PhD; Second in a Series: Postcard from the Cutting Edge: ASCO in Chicago | Dr. May travels to the Heartland for a major cancer conference, and returns home to Montana with valuable information that enables one of his patients to gain insurance approval for a newly FDA-approved prostate cancer drug
- 3/8/2013 Androgen Deprivation Therapy Increases Risk for Gallbladder Disease | Because male hormones, or androgens such as testosterone, fuel prostate cancer growth androgen deprivation therapy (ADT) is a mainstay in the treatment for certain forms of prostate cancer and has been proven to improve survival times
- 2/26/2013 Anticoagulant Use During Chemotherapy and Prostate Cancer Survival Rates | The study retrospectively reviewed the medical charts of 247 men with metastatic, treatment resistant prostate cancer
- 2/26/2013 SNPs and Prostate Cancer and Radiation Therapy | PCF-funded researchers led by Dr. Lorelei Mucci presented data at the 2013 Genitourinary Cancers Symposium in Florida
- 2/21/2013 Role of Radical Prostatectomy in Patients With Prostate Cancer | Even in the presence of screening, there is benefit to radical prostatectomy (RP) in prostate cancer patients
- 2/8/2013 Redux REDUCE-Chemoprevention for Prostate Cancer Remains Controversial | New Study Finds No Increased Risk of High-Grade Prostate Tumors in Men Taking Dutasteride; However, Study Unlikely to Sway Detractors of Using the Drug as a Chemoprevention Agent
- 1/31/2013 NEJM Study on Long-Term Side Effect Functional Outcomes After Treatment for Localized Prostate Cancer | At two years post diagnosis, men who had surgery were about six times more likely to have urinary incontinence compared to men who received radiotherapy
- 1/24/2013 Study Brings Science One Step Closer to a Completed Cityscape Map of Epigenetic Changes That Drive Metastatic Prostate Cancer | Now a new study in Science Translational Medicine that analyzed the whole genomes of 13 men who had expired from metastatic prostate cancer finds epigenetic changes that were consistent and stable in individual patients
- 1/11/2013 Johnson Gets Expanded Approval for Zytiga Cancer Treatment in EU | Johnson & Johnson's (JNJ) Janssen-Cilag International NV said it has received approval from the European Commission that allows its cancer treatment Zytiga to be adopted in the European Union earlier in the treatment process
- 12/17/2012 New Research Aims To Make Cancer Drugs With 3D Printers | Over the last year, 3D printers have inspired a lot of futuristic ideas. One of the more lofty ideas was the creation of medicine via 3D printing
- 12/13/2012 Phase II Clinical Trial for Galeterone Begins Treating First Patient | The Phase II, ARMOR2 trial will evaluate galeterone in 196 patients, who are either treatment-naïve, or those whose disease has progressed despite therapy with Zytiga (abiraterone acetate)
- 12/10/2012 J&J’s Zytiga Wins Approval for Earlier Use in Prostate Cancer | In this preclinical study, the researchers found that their novel drug was indeed activated by PSA in prostate cancer cells and lead to P13K inhibition and cancer cell death
- 11/16/2012 Non-Invasive, Biodegradable Brachytherapy Treatment Makes Headlines | Brachytherapy is a common treatment used for prostate cancer patients.
- 11/08/2012 New Targeted Therapy for Advanced Prostate Cancer Shows Anti-tumor Activity in Clinical Trials | Few available treatment options exist once prostate cancer has spread to other parts of the body and has failed to respond to therapies that involve blocking the male hormone androgen.
- 10/2/2012 Protein Found in Prostate Cancer May Promote Cancer Growth and Progression | The protein PARP1 is known to play a crucial role in DNA repair.
- 10/01/2012 Men Have More Options in Prostate Cancer Treatments | Jim Kiefert of Olympia, Wash., has been battling prostate cancer for 23 years. The retired school administrator, 74, has never been more optimistic about his prospects than he is now.
- 9/26/2012 Published Study Finds Little Benefit in Prostatectomy vs. Active Surveillance | Using the leading active surveillance cohort of prostate cancer patients at Johns Hopkins University and computational disease modeling, scientists compared prostate cancer-specific deaths in patients under active surveillance versus those that went for immediate treatment post-diagnosis.
- 9/25/2012 Powerful Chemotherapy For Prostate Cancer Treatment's Underlying Mechanism Revealed | Study Suggests Role of Taxane-Based Chemotherapy Drugs May Be Underestimated and Should Be Re-examined to Improve the Drug's Effectiveness
- 9/19/2012 Multi Gene Predictive Signature to Discriminate Aggressive from Indolent Prostate Cancer May Allow Men to Avoid Unnecessary Treatments | Doctors know that the majority prostate cancers are slow-growing and non-lethal, but pinpointing exactly which cancers fall into this category has been historically difficult.
- 9/19/2012 How We Can Pick Up The Pace In The Race To Cure Cancer | I was totally uninformed and unprepared for what I was about to face when I received my diagnosis
- 9/13/2012 Medivation and Astellas Announce XTANDI (Enzalutamide) Is Now Available for Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel | XTANDI was approved by the U.S. Food and Drug Administration (FDA) on August 31, 2012. XTANDI is being distributed through a network of specialty pharmacies and specialty distributors.
- 9/10/2012 Androgen-Blocking Drug Wins Approval for Prostate Cancer | Men with advanced prostate cancer now have another treatment option, thanks to the approval August 31 by the U.S. Food and Drug Administration (FDA) of a pill that blocks androgen-receptor signaling and prolongs patient survival.
- 8/30/2012 Prostate Cancer Drug Zytiga Receives Priority Review by FDA | Zytiga represents a new class of medication that suppresses testosterone in a new way, lowering testosterone levels far below the levels achieved with current androgen suppressive medications.
- 8/30/2012 Prostate Cancer Gene May Determine Tumor Growth, Return | Scientists may have found a clue to one of the most vexing questions in cancer care
- 8/29/2012 Aspirin May Aid Cancer Recovery | Men treated for prostate cancer who took aspirin regularly for other medical conditions were less likely to die of their cancer than patients who weren’t taking aspirin
- 8/22/2012 Nanotechnology in Personalized Medicine | Introduction to nanomedicine
- 8/16/2012 Enzalutamide Prolongs Survival in Treatment-resistant Prostate Cancer Patients | Androgen (male hormone) signaling remains a major driver of prostate cancer growth and spread, its activity mediated by the Androgen Receptor (AR).
- 8/14/2012 Experimental Theranostic Nanoplexes for Prostate Cancer Therapy | Imaging techniques have become a hot research concentration in the field of diagnostics, especially in prostate cancer.
- 8/13/2012 Prostate Cancer Drug Abiraterone Approved by Scottish Medicines Consortium | A drug which can extend the lives of men with incurable prostate cancer has been approved for use in Scotland.
- 8/9/2012 Prostate Cancer Microenvironment: New Targets for Cancer Control | Prostate cancer patients who undergo chemotherapy have a high probability of developing treatment resistance.
- 8/1/2012 Prostate Cancer Drug, Abiraterone, Approved for NHS Use in Northern Ireland | A "breakthrough" drug which can prolong the lives of men with terminal prostate cancer is to be made available to NHS patients in Northern Ireland.
- 7/24/2012 MDV3100 (Enzalutamide) Granted Priority Review Designation by the FDA | MDV3100 is a therapeutic agent for men with advanced prostate cancer who have failed both hormone and chemo therapies
- 7/2/2012 Prostate Surgery Tied to Need for Bladder Surgery | One in 20 men who have their prostate gland removed may need a second surgery for severe loss of bladder control, new research from Canada suggests
- 6/28/2012 Side Effects Persist After Prostate Cancer Treatment | Men who are treated for prostate cancer may still suffer side effects from treatment up to a decade later, a new study finds.
- 6/27/2012 Astellas and Medivation Announce European Regulatory Submission |
- 6/19/2012 Zytiga Approved in Australia and Singapore | The treatment is currently awaiting approval from the Food and Drug Administration (FDA) in the United States.
- 6/18/2012 Prostate Cancer Drug Zytiga Seeks Extended Label in U.S. and Europe | Zytiga is currently approved in combination with prednisone for men who have received prior docetaxel-based chemotherapy.
- 6/12/2012 Investigational Drug Nears FDA Approval | In early June, researchers presented data on the investigational drug during the American Association of Cancer Research (AACR) annual meeting.
- 6/2/2012 Laying the Foundation For a Cure | As drug treatments for prostate cancer dominate the news at ASCO, we look back at how abiraterone (Zytiga) made its way onto the A list.
- 6/2/2012 UCSF Reports on Abiraterone Clinical Trial, PCF-Funding Leads Innovative Research Team | Lead author Charles J. Ryan, MD, at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco and his research team presented interim data results from a Phase III clinical trial on abiraterone acetate in metastatic, chemo resistant prostate cancer patients.
- 6/1/2012 MDV3100 Expanded Access Program for Use in Metastatic Prostate Cancer Patients | Medivation and Astellas, the manufactures of MDV3100, applied for a New Drug Application with the FDA in early May 2012.
- 5/23/2012 Role of Fusion Gene Holds Promise of Therapy for Cancers, Including Prostate | Prostate Cancer Foundation funded research has shown that 50 percent of all prostate cancers carry the TMPRSS2-ERG gene fusion, an abnormal juxtaposition of TMPRSS2 and ERG genes
- 5/17/2012 Dendreon’s Provenge Works Best for Patients With Low PSA, Scientists Say | The study wasn’t designed to get a statistically significant answer to this question, meaning the finding could be a fluke.
- 5/15/2012 Benefits of Zytiga Out Rule Cost Concerns, Drug Approved In United Kingdom | The decision came after NICE ruled against Zytiga eight months ago, stating that its benefits didn’t justify its cost.
- 5/15/2012 U-M School of Dentistry Researchers Discover Possible Link between One Form of Chemotherapy and Bone |
- 5/7/2012 Harnessing the Body's Immune System to Fight Prostate and Other Cancers | Laurie McCauley, professor in the Department of Periodontics and Oral Medicine at the University of Michigan School of Dentistry is the second U-M School of Dentistry researcher to deliver new data relating to prostate cancer and metastases to the bone.
- 5/7/2012 Scientists Identify Therapy-Resistant Subset of Tumor-Propagating Prostate Cancer Cells | The resistance of prostate cancer (PCa) to androgen deprivation therapy (ADT) and chemotherapy may be due to a subset of cancer cells characterized by low levels of prostate specific androgen (PSA) expression, scientists claim.
- 4/27/2012 Robotic Surgery Dominant in Prostate Cancer | Fueled in part by fewer complications, robotic-assisted radical prostatectomy (RARP) has surpassed open surgery as the predominant surgical approach to localized prostate cancer, analysis of a national database showed.
- 4/10/2012 Bone Microenvironment Important in Approaching and Treating Prostate Cancer | Evan Keller, DVM, PhD, a Prostate Cancer Foundation funded researcher at the University of Michigan, found that targeting the bone microenvironment may help guide treatment approaches for prostate cancer patients.
- 3/29/2012 CD47 Protein Is an Actionable Target in Multiple Cancers | Reported by Time, a working group of scientists at Stanford University School of Medicine, led by professor of pathology Irving Weissman, successfully tested an antibody treatment that blocks the protein CD47
- 3/21/2012 Cadmium Studied in Prostate Cancer at Marshall University | A report from Marshall University found preliminary data on cadmium, a toxic metal found in industrial workplaces, and it’s possible role as a key driver in the development of prostate cancer.
- 3/20/2012 One Size Does Not Fit All for Prostate Cancer Treatment | A recent study in the Achieves of Internal Medicine found that during the past decade, some men with low-grade prostate cancer may have been treated with therapies that are too aggressive.
- 3/8/2012 No Increased Risk of Cardiovascular Death With Androgen Deprivation Therapy for Prostate Cancer | New results from a meta-analysis show no apparent association between androgen deprivation therapy (ADT) and cardiovascular events and death in men with prostate cancer.
- 3/8/2012 FDA Approved Treatment Used for Novel Application | Zytiga (abiraterone acetate) was approved by the Food and Drug Administration in early 2011 for the treatment of castration-resistant, metastatic prostate cancer following docetaxel chemotherapy.
- 3/7/2012 PCF Chairman Michael Milken Joins Focused Ultrasound Foundation Council | The Focused Ultrasound Foundation announced today that medical research activist, philanthropist and financier Michael Milken has joined its Council, a select group of advisors and advocates who are helping to advance the organization's mission.
- 3/1/2012 Nymox Announces U.S. Phase 2 Clinical Trial of NX-1207 for New Indication-Prostate Cancer | Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce the initiation of a Phase 2 U.S. clinical trial to evaluate the company's NX-1207 drug for the treatment of low grade localized prostate cancer.
- 2/27/2012 Initial Funding for Cancer Vaccine Leads to Further Progress | Since the early 1990’s, the Prostate Cancer Foundation has funded early research on immunotherapies and their role in prostate cancer.
- 2/7/2012 Study Analyzes Side Effects, Costs of Prostate Cancer Treatment | Nearly a quarter of a million men are diagnosed with prostate cancer each year, and while survival rates are increasing, toxicity of treatments has not been well studied over a long period of time.
- 2/7/2012 Abbreviated Radiotherapy Shows Promise in Prostate Cancer | Dramatically condensing radiation treatment for early prostate cancer into just five fractions produces good results without much toxicity, an early-phase study suggested.
- 2/1/2012 Seed Therapy for Prostate Cancer May Zap Fertility | Radioactive "seeds" that are sometimes used to treat early prostate cancer may do widespread damage to the DNA in a man's sperm, a small study finds.
- 2/1/2012WSJ Article Shows Rapid Progress in Prostate Cancer | Research and treatment advances continue to climb
- 1/31/2012 PCF-Funding Leads to New Bone Scale Index to Measure Remissions in Bone Metastases | Important Tool for Physicians to Use on Patients
- 1/30/2012 Brown Fat Plays Important Role in Weight Management, Prostate Cancer | PCF-funded investigator explores its role
- 1/24/2012 Drug May Slow Early Prostate Cancer: Study | Typically used for an enlarged prostate, it could prevent need for aggressive treatment
- 1/23/2012 Androgen Receptor Pathway Agents Continuing to Change the Landscape of Prostate Cancer |
- 1/4/2012 Cancer Incidence, Death Rates Continue to Drop: Report | One million lives saved, largely because of improved prevention, detection and treatment
- 11/2/2011 Radiation Plus Hormone Therapy Extends Life in High-Risk Prostate Cancer | But, surgery might even improve survival more, expert says
- 8/12/2011 Many Men Underestimate Prostate Surgery Side Effects | Incontinence, impotence often worse than anticipated, study finds
- 7/13/2011 For Some Prostate Cancer Patients, Combo Treatment Improves Survival | For men at 'intermediate risk,' radiation plus 4 months of hormone therapy improves survival, study finds
- 6/30/2011Medicare to Cover Cost of Provenge |The decision today by the Centers for Medicare & Medicaid Services (CMS) to immediately start covering Provenge is good news for many prostate cancer patients with advanced metastatic disease.
- 6/6/2011 Jury Still Out on Radiation for Early Prostate Cancer | There's too little evidence to say it's superior to 'watchful waiting,' study says
- 5/17/2011 Surgery Viable for Advanced Prostate Cancer, Study Finds | After removal of their prostate gland, 80% of patients survived 20 years
- 5/16/2011 Prostate Cancer Survival May Be Especially Tough on Gay Men | Post-treatment quality of life scores worse than for heterosexuals, study finds
- 5/4/2011 Aggressive Treatment May Be Beneficial for Early Prostate Cancer | In men under 65, death risk was lower than for those who chose watchful waiting
- 4/28/2011 FDA Aproves Zytiga (abiraterone acetate) for Late-Stage Prostate Cancer | The Prostate Cancer Foundation (PCF) applauds the approval of Zytiga (abiraterone acetate), a once-daily oral agent, for the treatment of castration-resistant, metastatic prostate cancer following docetaxel chemotherapy
- 3/28/2011 Short Course of Hormone Therapy Boosts Prostate Cancer Survival | Coupled with radiation, six months of treatment improved odds in locally advanced cases, researchers found
- 2/23/2011 Newer Drug May Help Prevent Fracture in Men With Prostate Cancer | Slightly fewer patients on denosumab experienced 'skeletal events' than those on Zometa, study found
- 12/1/2010 FDA Panel Votes Against Drugs Said to Prevent Prostate Cancer | Experts were concerned about rare risk of aggressive tumors in patients using the meds
- 11/30/2010 Study Backs 'Active Surveillance' for Low-Risk Prostate Cancer | But the alternative to immediate treatment isn't for all men, researchers say
- 11/17/2010 Medicare Panel Endorses Vaccine for Prostate Cancer Patients | Provenge extends survival by about four months on average and costs $93,000 per individual
- 10/20/2010 FDA Calls for New Warnings on Some Prostate Cancer Drugs | Hormonal meds linked to slight increase in risk of heart disease, diabetes
- 9/27/2010 Surgery a Help for Aggressive Prostate Cancer | Researchers report radical prostatectomy can extend survival rates
- 9/16/2010 Sex Problems Vex Men Long After Prostate Surgery | Sexual problems appear to be more distressful to men after prostate-removal surgery than urinary problems do, a new long-term follow-up study shows.
- 9/1/2010 No Risk Seen From Delaying Prostate Cancer Surgery | Patients who delayed surgery by over a year had similar outcomes as those who opted for immediate treatment
- 5/4/2010 As FDA Eyes Prostate Cancer Drugs, Experts Urge Caution | Hormonal meds linked to heart risks, but men should not abandon them
- 5/3/2010 FDA Reviews Side Effects From Prostate Cancer Therapy | Doctors urged to consider risks of hormone treatment, inform patients